Author:
Brooks Benjamin Rix,Kurent Jerome E.
Reference82 articles.
1. Allen, K.D., E.L. Kasarskis, R.S. Bedlack et al. (2008). The National Registry of veterans with amyotrophic lateral sclerosis. Neuroepidemiology 30 (3): 180–90.
2. ALS Association (2016). Guidance for Industry. Drug Development for Amyotrophic Lateral Sclerosis http://www.alsa.org/advocacy/fda/assets/als-drug-development-guidance-for-public-comment-5-2-16.pdf.
3. Andrews, J.A., C.E. Jackson C.E., T.D. Heiman-Patterson, et al. (2020). Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, https://doi.org/10.1080/21678421.2020.1771734
4. Barth, S.K., H.K. Kang, T.A. Bullman and M.T. Wallin (2009). Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. Am J Ind Med. 52 (9): 663–70.
5. Beard, J.D., L.S. Engel, D.B. Richardson, M.D. Gammon et al. (2017). Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis survival. PLoS One. 12 (10): e0185751. https://doi.org/10.1371/journal.pone.0185751.